{"name":"Intellia Therapeutics","slug":"intellia-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxObW5BWHc4SzNGck5seXQ0ZDN0QU5fUmZVSkhyUnVmRUpQcmNFX3pMYkwzcnpHZVVBcVVJckxiV0dubEM0eDVvR0JudHJpX3JzN09tUFZ6SGUwT3BuaVB5LVlGMkhVNVRjelk5clpZV3EwYTVMTHRkY2JLX3FnZkZVMlZUVjVHaHp4S1ZFanpxbTFaTEgxb0xOci1vSFZMVWhkWW5neTlXVXNpRXdIQktCeDFGUDE5VkpPcDhTREt3WU1UcHRCWnBSTFNTQW9TS3FsRVZZV0trZks?oc=5","date":"2026-03-02","type":"regulatory","source":"reuters.com","summary":"Intellia gets FDA nod to resume second gene therapy trial after safety pause - reuters.com","headline":"Intellia gets FDA nod to resume second gene therapy trial after safety pause","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPYjQ5bTFrMlJMVWEwZ1AtRTU1R3BkRDg0ZHRtWTAxY3FRRXRoVWVRZjhscmFfYU9Fd1l0bk5FVUpwSWpKdUQxcXZRRlJyOXYyY3V3eENIeUhVTkhSY1Y3X2tiMENpTWFpXzhjNHgySmg2ajJrRTdvNFBJNGFNUDdhV0QyQzZ6MmxUelZKeGgxaG5FNTluOUNiVXVJZw?oc=5","date":"2026-01-27","type":"regulatory","source":"BioPharma Dive","summary":"FDA lifts hold on an Intellia CRISPR drug trial - BioPharma Dive","headline":"FDA lifts hold on an Intellia CRISPR drug trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNMVY5VzhwV0Z0aFhDRy1DVE5mY1lvU2xOZGtvRExDWXptUGdqb1hiT3RaSkZpX0VzNFM0NUExakJ2eDhITWkwNHFkOHpmVVlYWndsUExzMjV1Z2J1Nzg1VjkzX2tvUjk4RTlfZzE0X3dHbkN2ck9YdEZvaWZmOTc5M01jOWFNMjhhUzJ5eHlPa3ZsVnRVaUlSV0k0RWkyNGdudmljR0RFMG5PV01YZWlydUlCcVFtQ2Z2ZXBKQXlqMG1qLW8?oc=5","date":"2026-01-27","type":"regulatory","source":"Intellia Therapeutics - investor relations","summary":"Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN - Intellia Therapeutics - investor relations","headline":"Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN - Intellia T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPZWU0WG5MUEd4eUdOZXhweWxxeWNDX1dNbFRIYmIzdjVhaDl4NjVRTTFsSTU2ZmpzZ2hGLUlZMVJQZFUxRDN4NWROelYxTlY0enIwYmdXaDdMcktxS04tbGpqWE5JN1ZRR193OHdiQzlRbUtTWHJWVndCVkJPT3BXcnZXZFVaYlRFZlZGWllYN0FwSzA?oc=5","date":"2026-01-27","type":"regulatory","source":"The Pharma Letter","summary":"Intellia shares leap as FDA lifts trial hold - The Pharma Letter","headline":"Intellia shares leap as FDA lifts trial hold","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOU0lmZ3EzYS10MW9hTWJ0UnVNYVlMWTl6US1qbTFXdkRjMkx3OTNtWWh1ZzJBZGl6M3hTTkxsZ0UyZkJOUzFNRVNxWUJpbDJYb05TOFRWa2pHbzhrdlRQMXhFWWlnT1ZjdWFUZzlxTVZEUjdPdUhmRTZtM0g0YlBHaUttbFBYSV84S0E1Y0VtTFJvaVhiNVUwT3BwM3Z2QlhyS25uYnhaVTUyUDAzY2RIcTZ5VkhFb2M?oc=5","date":"2026-01-15","type":"trial","source":"Clinical Trials Arena","summary":"JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death - Clinical Trials Arena","headline":"JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPSUMwdk52SlBSU09rdE40OXFTaVZ3RVFXOEFpOTg5MlN1Yl9pTHBualN6WnE2d0xyd2t2S080eExkWHBHMW9rNDdHM0RtaVlhQWg1aEtfM2FlQ3dULUkxdFZwQlpEbjM3OENoQjZFbWVhSmtFSU16YWdDaENhdFFTWDExbDRlQlJHTTdLc2xydFBuUXhDT2ppQnkzNk8?oc=5","date":"2025-11-07","type":"trial","source":"Investor's Business Daily","summary":"Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies - Investor's Business Daily","headline":"Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQb3lIeTgyNXJ2ZFVJRTFpeE1jTjM1SHRIcDNQQUZtSUtRWFJXaUd2WGNWTHZpSkd1SXVtUXJydkVQRkt2UlhnM1JFUU15dWVrdzUzeVBRR1FRN3BXdlh4QnRGanBiTE9mcVZheTBJaFNiR3FENFVwVGZ4X2pwUHJrRl9qcU01cW1TNFlOVzRSbzJmQmxiOHBEX05vOF9CR1ZrQUlfQ3VDekxVbjRZd1JN?oc=5","date":"2025-10-31","type":"regulatory","source":"MedCity News","summary":"Liver Complications Lead FDA to Stop Tests of Intellia Gene-Editing Therapy for a Rare Disease - MedCity News","headline":"Liver Complications Lead FDA to Stop Tests of Intellia Gene-Editing Therapy for a Rare Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE1VUHhMRjZFa1VRUVUxSEhpemFJbVprVHBWNGdTb21IeERjOFptYWZQY21GZW5qVkYwNDZ6eVFiS2sxeU42Vl9oVzgzaHh0elpLcDd3TDRnTzFvSE81OE1LcHpHUHBUVnZFTUp3bm14enc?oc=5","date":"2025-10-30","type":"deal","source":"statnews.com","summary":"Biotech might be tiny but the dealmaking is mighty - statnews.com","headline":"Biotech might be tiny but the dealmaking is mighty","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOTFBVbU9KUjZIWE5yVkFzSS10NjlFM2pQRTRfNnp1T1RnTHRVVHlHY0QxbExvVFp1TE1IV2tXSWJrWTBZY3JTdEN1ZXVFckxMM0ZrMk5jdEZhT2hfQVpIeG9QRXRKWEU1b1pHbk1zZmdVajVqWnFIam92OTJBRW5xbDJ1QTRIVl9PazFReUtHSzRGM25HSTZwT05jbnhNWDNfLVlrTlRLd2QwSjM0MEVQWWhaTF9FemIzS2ZxREg5NGhRZw?oc=5","date":"2025-10-27","type":"trial","source":"Intellia Therapeutics - investor relations","summary":"Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - Intellia Therapeutics - investor relations","headline":"Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - Intellia Therapeuti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE85SFdHd18xNWFRa0c4bVFTbnRGbXdLempfV2lZNHFGZHQtb0sxUWhFc3dPN0xhaHRJbnNDbG50ZWhkSU8yamgzdlV4YlRMV3pxOUY4?oc=5","date":"2025-10-27","type":"trial","source":"FirstWord Pharma","summary":"Intellia tumbles after serious liver toxicity pauses Phase III trials - FirstWord Pharma","headline":"Intellia tumbles after serious liver toxicity pauses Phase III trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOV3NJLTlob3ZldHdJeWtpNGVDdVhjUWxrLUV6NnZDb2RBZDJBSDBFME00VS1lWkJTeHhDNGs0SWhxZ0ZvMF9IckdLNngxMWVwSGZHMzc5bGltNllTSUo0UUFNM3BNMFBsMnNyTUJOWGVmMXNnMVBpZ001LTVMV1FGRFItSFowMnZ3WHc?oc=5","date":"2025-10-27","type":"trial","source":"pharmaphorum","summary":"CRISPR biotech Intellia plummets as trial paused for safety - pharmaphorum","headline":"CRISPR biotech Intellia plummets as trial paused for safety","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOZEJlMzJjZ19ybDFwVERNaEZ5bHgyOHZlUDNvQ0tCLWRPdFpEazlaSkpiMTFtNlhqbWhKV19VTWR0ZVhvTGthem0xX0J2eG5vRUlyNjBtV1pxNThCUmNCakRJQ2lpbE5FLUR1czZiTFBveGpOVHBQdHBmWUg3V3llSVdHUGpEekZIMjFZQVEyemZ4MjljX1hFWXJ2Q2JjVWxRRldVc3dENXN6NjM5SzQ1UXRlU3NFelpMR2c?oc=5","date":"2025-09-19","type":"trial","source":"seekingalpha.com","summary":"Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis (NTLA) - seekingalpha.com","headline":"Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis (NTLA)","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}